6月25日，查尔斯河盘中上涨5.09%，报208.23美元/股，成交额3885.78万美元。
消息面上，公司近期召开财年年报业绩会议，管理层强调自第三季度以来订单出货比持续改善，生物技术融资环境显著好转，带动需求回升。摩根士丹利近日将查尔斯河评级从"同等权重"上调至"跑赢大盘"，目标价从185美元上调至220美元。此外，RBC Capital亦给予"跑赢大盘"评级及215美元目标价，认为公司有望在下半年表现超预期。FactSet统计的分析师平均目标价为220.29美元，当前股价仍有上行空间。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.